H5N1/Vogelgrippe seit 1997: Der Evergreen unter den Methoden, Panik zu verbreiten [Neues von der WHO]

Was denken Sie, seit wann H5N1 als „Gefahr“, aufgrund einer potentiellen Pandemie für Menschen weltweit aufgebaut wird?

Nun, aufgetaucht ist das Virus 1997 in Hong Kong.

Der übliche Massenmord an Vögeln, soll der vermeintlichen Gefahr für Menschen ein Ende bereitet haben. Indes, das Potential von H5N1, als Methode, Menschen Angst zu machen, wurde schnell erkannt, denn im Mai 1997 erkrankten 18 Personen in Hong Kong an H5N1 und 6 davon sind verstorben. Daraus, aus 18 Infektionen und sechs Toten hat nicht zuletzt die EU geschlossen, dass „an influenza pandemic could be imminent„, weshalb Regierungen der Mitgliedsstaaten der EU mit vorbeugenden Maßnahmen reagiert haben. Indes, den vorbeugenden Maßnahmen ging ein Treffen, einer so gennanten ad- hoc-Gruppe zu übertragbaren Krankheiten am 14. Januar 1998 voraus, initiiert vom DGV, der Direction General 5 der Europäischen Kommission.

Schon Anfang 1998 wurde die Sorge, vielleicht auch Hoffnung, immerhin lässt sich mit H5N1 viel Geld verdienen, die Sorge dass H5N1 zur Pandemie werden könnte, ausgiebig ausgebreitet und die Teilnehmer der ad-hoc-Gruppe haben zu ihrem Schrecken festgestellt, dass es keine Impfstoffe gegen das gerade erst gefundene Virus H5N1 gibt. Wie gewöhnlich, so hat auch diese Feststellung dazu geführt, dass Millionen Euro aus Steuergeldern in die Erforschung eines Impfstoffes gegen H5N1 geflossen sind.

Ein lukratives Geschäft.
Bester Beleg dafür ist die Anzahl der Impfstoffe gegen H5N1, an denen derzeit geforscht wird.
Am besten Sie scrollen drüber:

NCT Number	Study Title	Sponsor
NCT03038776	Recombinant H7 Hemagglutinin Influenza Vaccine Trial	Vaxine Pty Ltd
NCT00530660	Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)	Ology Bioservices
NCT02743676	A Retrospective, Observational Registry of Participants With Avian Influenza Infection	Hoffmann-La Roche
NCT04669691	A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine	Seqirus
NCT03651544	The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
NCT01142362	Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults	Inovio Pharmaceuticals
NCT01107262	Avian Influenza Studies In Lebanon	St. Jude Children’s Research Hospital
NCT00311480	Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects	Novartis
NCT01258062	Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults	Ology Bioservices
NCT00417560	Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses	Centers for Disease Control and Prevention
NCT03834376	Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection	Janssen Research & Development, LLC
NCT03472976	H5N1 With or Without Topical Aldara in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01184976	Study Of VGX-3400, H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males	GeneOne Life Science, Inc.
NCT00900991	Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children	Sinovac Biotech Co., Ltd
NCT01698060	Immunogenicity of ND1.1 by Delivery Directly to the Ileum	Vaxart
NCT03755427	A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine	Shanghai Institute Of Biological Products
NCT00489931	Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00884182	Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children	Sanofi Pasteur, a Sanofi Company
NCT00841763	Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects	Novartis
NCT02078674	A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant	Novavax
NCT00783926	Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)	Ology Bioservices
NCT00640874	A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza	Kirby Institute
NCT03682120	Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01594320	A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1	Novavax
NCT03745274	Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults	AVIR Green Hills Biotechnology AG
NCT00439530	Pharmacologic Study of Oseltamivir in Healthy Volunteers	Mahidol University
NCT02839330	A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age	Seqirus
NCT00337896	T and B Cell Response to Avian Flu Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00439335	Higher Dose Intradermal H5 Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00516035	Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00478816	Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines	Novartis Vaccines
NCT00537524	Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years	Novartis Vaccines
NCT01044095	Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus	Armed Forces Research Institute of Medical Sciences, Thailand
NCT01995695	Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00347672	Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00545701	Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults	Sanofi Pasteur, a Sanofi Company
NCT01897701	A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1	Novavax
NCT00519389	Safety, Reactogenicity and Immunogenicity of an H5N1 VLP	Novavax
NCT02586792	H7N9 Boost in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02095444	Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection	S-Evans Biosciences Co., Ltd.
NCT01323946	Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children	GlaxoSmithKline
NCT00695669	A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64	GlaxoSmithKline
NCT00848029	Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules	Novartis Vaccines
NCT00415129	Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly	Sanofi Pasteur, a Sanofi Company
NCT01382329	H5N1 Vaccine Study in Japanese Adults	Ology Bioservices
NCT00841646	Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects	Novartis Vaccines
NCT01573312	H5N1 Vaccination With and Without AS03: Systems Biology Analysis	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00382980	Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00488046	Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00680069	H5N1 (Clade 2) Vaccination of Adults and Elderly	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00240968	H5 Booster After a Two Dose Schedule	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01640691	Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults	Adimmune Corporation
NCT01236040	Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 – 49 Years Old	GlaxoSmithKline
NCT02719743	A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals‘ GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age	GlaxoSmithKline
NCT00719043	Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years	GlaxoSmithKline
NCT03739229	Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine	Research Institute of Influenza, Russia
NCT01657929	H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers	Access to Advanced Health Institute (AAHI)
NCT00532792	A/H5N1 Dose Ranging Study With Adjuvant Patch	Intercell USA, Inc.
NCT00895544	Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults	Ology Bioservices
NCT01942265	H7N9 Mix and Match With AS03 and MF59 in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02480101	Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine	Research Institute of Influenza, Russia
NCT01147068	Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults	Protein Sciences Corporation
NCT01766921	Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects	Novartis Vaccines
NCT02151344	Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03312231	Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00311727	Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01086657	An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re…	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03581903	A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00519064	Immunogenicity and Safety of an Adjuvanted Inactivated Subunit Influenza Vaccine to Those of a Non-adjuvanted Inactivated Subunit Influenza Vaccine, When Administered to Adults Affected by Chronic Diseases	Novartis Vaccines
NCT02206464	H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo…	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03369808	A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine	Shanghai Institute Of Biological Products
NCT01195038	Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults	UMN Pharma Inc.
NCT00561184	Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine	Novartis Vaccines
NCT01675284	A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine	Medigen Biotechnology Corporation
NCT00640302	A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza	Kirby Institute
NCT02680002	Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant	Biomedical Advanced Research and Development Authority
NCT01052402	Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents	Ology Bioservices
NCT00110279	Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02091908	Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions	Seqirus
NCT00230750	Inactivated Influenza A/H5N1 Vaccine in the Elderly	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00853255	Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01403155	A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001	Inovio Pharmaceuticals
NCT00297050	Safety and Dose Study of Peramivir for Influenza Treatment	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03345043	Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects	ModernaTX, Inc.
NCT00755703	Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.	Altimmune, Inc.
NCT01045564	Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure	GlaxoSmithKline
NCT00240903	Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02335164	A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults	Vaxine Pty Ltd
NCT03014310	H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00711295	Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups	Ology Bioservices
NCT01250795	Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults	Fraunhofer, Center for Molecular Biotechnology
NCT01928472	Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years	Novartis Vaccines
NCT00908687	A/H5N1/LT Dose Ranging Study	Intercell USA, Inc.
NCT00298233	High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00434733	Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects	Novartis
NCT00382187	Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults	Novartis Vaccines
NCT00280033	H5 Adult – Chiron Study of Bird Flu Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00660257	Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine	Sinovac Biotech Co., Ltd
NCT01086566	Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines	National Institute of Allergy and Infectious Diseases (NIAID)
NCT05422326	A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed	Seqirus
NCT00868218	Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults	Rebecca Cox
NCT01074736	Host Genetic Susceptibility to Avian Influenza A/H5N1	South East Asia Infectious Disease Clinical Research Network
NCT02295813	Safety and Pharmacokinetics Study of FBF001	Fab’entech
NCT00694213	Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)	Vical
NCT00311649	Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01999842	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals‘ Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age	GlaxoSmithKline
NCT01938742	H7N9 Mix and Match With MF59 in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01443936	Experimental AD4-H5-VTN Vaccine in Healthy Volunteers	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00402649	Open-Label Study of H5 Vaccine in Participants of Protocol 04-077	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02171819	Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) – Phase 1	Institute of Vaccines and Medical Biologicals, Vietnam
NCT01511419	Safety Trial of Live Attenuated Influenza (H7N3) Vaccine	PATH
NCT00133536	A/H5N1 Vaccine in Healthy Children Aged 2-9 Years	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00310206	H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00294099	H5 Vaccine Alone or With Aluminum Hydroxide in Elderly Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00517517	Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)	Ology Bioservices
NCT00296634	H5 Vaccine Alone or With Adjuvant in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02177734	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals‘ Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age	GlaxoSmithKline
NCT01353534	Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine	Intercell USA, Inc.
NCT01317758	H5N1 Mix and Match With AS03	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00912496	Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01596725	A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2	Novavax
NCT02691130	Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults	BiondVax Pharmaceuticals ltd.
NCT02229357	Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine	Mahidol University
NCT01776541	Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults	Novartis Vaccines
NCT01037634	Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01578317	Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00115986	A/H5N1in Adult – Aventis	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01443663	Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00664417	Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine	Sanofi
NCT03738241	2017 A/H7N9 IIV Revaccination	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02624219	H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03283319	Panblok H7 Vaccine Adjuvanted With AS03 or MF59	Biomedical Advanced Research and Development Authority
NCT00349141	Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)	Ology Bioservices
NCT01310413	Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age	GlaxoSmithKline
NCT00812019	Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)	Seqirus
NCT05397119	A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults	BlueWillow Biologics
NCT01298206	Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon	St. Jude Children’s Research Hospital
NCT01389466	Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers	Green Cross Corporation
NCT00481065	Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects	Novartis
NCT01379937	A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals‘ Influenza Vaccine in Children	GlaxoSmithKline
NCT01910519	Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00814385	Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04	University Hospitals, Leicester
NCT00491985	Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children	Sanofi Pasteur, a Sanofi Company
NCT00408109	Safety Study of Avian Flu Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00771615	Immunogenicity & Safety of GSK’s Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years	GlaxoSmithKline
NCT01656356	Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers	Mahidol University
NCT02612909	A Safety and Immunogenicity Study of IVACFLU-A/H5N1	Institute of Vaccines and Medical Biologicals, Vietnam
NCT02107807	Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine	Seqirus
NCT00457509	Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults	Sanofi Pasteur, a Sanofi Company
NCT00428753	China Case Control Avian Influenza	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00703053	H5N1 Priming and Boosting Strategies	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01317745	H5N1 Mix and Match With MF59	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01676675	A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults	Jiangsu Province Centers for Disease Control and Prevention
NCT00397215	Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age	GlaxoSmithKline
NCT00620815	Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above	Novartis Vaccines
NCT00462215	Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)	Ology Bioservices
NCT01774032	H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older	Ology Bioservices
NCT01150552	Studies of Avian Influenza Transmission to Humans in Egypt	St. Jude Children’s Research Hospital
NCT00709800	Pandemic Influenza Plasmid DNA Vaccines (Needle)	Vical
NCT01658800	Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49	VaxInnate Corporation
NCT00734175	Safety of and Immune Response to Recombinant Live-Attenuated Influenza H6N1 Virus Vaccine Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00311675	St. Jude Open Label H5 Trial	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00922259	Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03318315	Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00380237	Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03330899	Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil	Butantan Institute
NCT03497845	Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59	Biomedical Advanced Research and Development Authority
NCT02274545	Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01335347	Safety Study of an Oral Vaccine to Prevent Avian Influenza	Vaxart
NCT00309647	Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age	GlaxoSmithKline
NCT00980447	Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults	UMN Pharma Inc.
NCT00984945	Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults	Medicago
NCT00356798	Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects	Sinovac Biotech Co., Ltd
NCT01006798	Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1	Emergent BioSolutions
NCT00319098	Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above	GlaxoSmithKline
NCT01416571	Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals‘ Monovalent Pandemic H5N1 Vaccine in Adults	GlaxoSmithKline
NCT00428493	Prospective Study of AI H5N1 in China	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02957656	Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02153671	Immunogenicity of H5N1 Vaccine Following H5N2	PATH
NCT00914771	Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects	Novartis Vaccines
NCT00383071	Development of Immune Globulin Treatment for Avian Flu	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01560793	Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years	VaxInnate Corporation
NCT01776554	Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children	Novartis Vaccines
NCT04789577	A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals‘ Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older	GlaxoSmithKline
NCT02213354	H7N9 Mix and Match With MF59 in Healthy Elderly Persons	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03701061	Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response	Emory University
NCT02436928	A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects	Medigen Vaccine Biologics Corp.
NCT03196661	Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population	Hualan Biological Bacterin Co. Ltd.
NCT01788228	Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure	GlaxoSmithKline
NCT00640211	A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B	Kirby Institute
NCT03816878	Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00776711	Vaccine for Prevention of Bird Flu	National Institute of Allergy and Infectious Diseases (NIAID)
NCT03589807	2013/2017 H7N9 Prime-Boost Interval	National Institute of Allergy and Infectious Diseases (NIAID)
NCT02251288	A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine	National Institute of Allergy and Infectious Diseases (NIAID)
NCT00900588	Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents	Sinovac Biotech Co., Ltd
NCT01987011	Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers	Green Cross Corporation
NCT02921997	H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses	National Institute of Allergy and Infectious Diseases (NIAID)
NCT01911754	Japanese Pediatric H5N1 Vaccine Study	Ology Bioservices

Da ist Geld drin…

Wenn so viele unterschiedliche Pharmafia-Unternehmen an ein und demselben „Impfstoff“ basteln, gegen ein Virus das sich nach wie vor standhaft weigert, von Mensch zu Mensch übertragbar in relevantem Ausmaß zu sein, dann muss man kein Prophet sein, um zu wissen, dass die hier versammelten finanziellen Interessen einen Weg finden werden, ihre Forschung zu Milliarden zu machen.

Indes, wie gesagt, es gibt da ein Problem.
Seit 1998 wird die Gefahr von H5N1/Vogelgrippe als Material, aus dem tödliche Pandemien sind, stetig beschworen, indes, H5N1 weigert sich standhaft.

Hier ein paar Beispiele der akademischen Panikmachen:

Beenden wir den Überblick an dieser Stelle, schon weil nach 2013 so gut wie keine Beiträge mehr zu finden sind, die sich mit dem Risiko einer Mensch-zu-Mensch-Übertragung von H5N1 befassen. Warum dem so ist, dazu mag die folgende Tabelle einen Erklärungsbeitrag leisten:

Abgesehen von einem kurzen Ausbruch in Ägypten spielt H5N1 im viralen Geschehen der Welt nach 2014 keine Rolle mehr und die Tatsache, dass Forschung den Verdacht nahegelegt hat, der Masseneinsatz von Impfstoffen gegen H5N1 in der Tierhaltung trage seinen Teil dazu bei, H5N1 virulent und endemisch zu halten, mag auch als Dämpfer für all diejenigen gewirkt haben, die mit ihren Forschungsergebnissen lieber nicht Gefahr laufen, ihre Finanzierung durch die Pharmafia zu verlieren.

Ergo wurde es ruhig um H5N1, so ruhig, dass sich die WHO-Mannen heute redlich mühen müssen, die Angst vor H5N1 künstlich zu schüren und wieder ans Laufen zu bringen:

Dr Tedros und Jeremy Farrar, gestern noch aktiv an der Vertuschung der Herkunft von SARS-CoV-2 beteiligt, heute der Chief Medical Adviser bei der WHO, vermutlich zur Belohnung, mühen sich redlich, die in Daten nicht belegbare Gefahr, die von H5N1 ausgeht, zu beschwörden und die Geldmaschine für Pharmafia-Unternehmen ans Laufen zu halten. Die Strategie hat sich in all den Jahren, die H5N1 nun schon beschworen wird, nie geändert.

H5N1 sei derzeit nicht von Mensch-zu-Mensch zu übertragen, so, Farrar, aber dennoch gefährlich, weil die Gefahr bestehe, dass es in Zukunft von Mensch-zu-Mensch übertragbar sein könnte. Eine Aussage, die auf nahezu jedes Virus zutrifft. Indes, H5N1 wurde in den letzten Jahren so prominent aufgebaut und wohl mit Hilfe von „Impfstoffen“ virulent unter Tieren gehalten (Webster et al. 2006), dass es derzeit keine Angst-Alternative zu H5N1 gibt. Also müssen die Angst-Agitatoren mit dem arbeiten, was sie haben. Herzlich wenig, wenn man die Tabelle mit den kumulativen Fällen von H5N1 unter Menschen betrachtet.

Deshalb wird derzeit gemolken, was geht, und Farrar gibt sich im letzten Video alle Mühe, das, was er nicht weiß, nicht etwa als Unwissen, sondern als Gefahr auszugeben, was, angesichts der Gefahr, dass uns der Himmel auf den Kopf fallen könnte, auf besonders ängstliche Naturen seine Wirkung nicht verfehlen dürfte. Er hat keine Ahnung, wie die Übertragung von Kühen zu Menschen, Tieren stattfindet, ob sie stattfindet, aber natürlich ist sie eine große Gefahr, was angesichts der Tatsache, dass Farrar keinerlei Daten hat, um die Gefahr zu quantifizieren, seltsam ist. Wenn man nichts weiß, wie kann man dann wissen, dass von dem, von dem man nichts weiß, eine große Gefahr ausgeht?

Wie auch immer.
Das ganze derzeitige Tohuwabohu basiert auf H5N1 unter Rindern und einem Farmarbeiter, der an H5N1 erkrankt ist. Indes, betrachtet man dessen „Krankheitsgeschichte“ etwas genauer, dann reibt man sich verwundert die Augen:

Ende März 2024 klagte ein Farmarbeiter über Rötung und Unwohlsein am rechten Auge. Festgestellt wurde eine subkonjunktivale Blutung und eine dünne, seröse Drainage. Ansonsten nichts. Normale Atmung, klare Lunge, kein Fieber, keine respiratorischen Symptome, nichts. Der Farmarbeiter hatte keinerlei Kontakt zu toten oder kranken Vögeln, aber mit gesunden und kranken Milchkühen, die ebenfalls gerötete Augen hatten, weniger Milch gaben, weniger Appetit aufwiesen und zuweilen eine erhöhte Temperatur hatten. Er trage Handschuhe, aber keinen Atem- oder Augenschutz bei der Arbeit mit Kühen. Ein PCR-Test war positiv für H5-Viren, die Symptome des Arbeiters verschwanden nach einer Behandlung mit Oseltamivir. Eine Analyse der Gensequenz des H5N1-Virus, das bei Arbeiter und Kühen festgestellt wurde, zeigte keinerlei Fähigkeit, an menschliche Zellen anzubinden:

Kurz: Wir sind immer noch da, wo wir 1997 waren, als H5N1 entdeckt wurde.

Keinerlei Hinweis darauf, dass H5N1 die Fähigkeit erlangen könnte, von Mensch-zu-Mensch übertragbar zu sein. Indes, es ist natürlich schon seit Jahren von Mensch zu Mensch übertragbar. Beim ersten Ausbruch von H5N1 in Hong Kong reiste die Mutter einer Infizierten an, um die Kranke zu pflegen. Sie infizierte sich mit H5N1 und verstarb. Indes legen Studien nahe, dass die Virenladung, die benötigt wird, um H5N1 von Mensch zu Mensch zu übertragen, so groß ist, dass man stundenlang dem Virus ausgesetzt sein muss, um überhaupt eine Wahrscheinlichkeit auf Ansteckung und Erkrankung zu haben (van Kerkhove 2014).

Aber selbst dann, wenn man die Daten, die oben in der WHO-Tabelle abgebildet sind, zur Grundlage nimmt, um die Übertragbarkeit von H5N1 statistisch zu quantifizieren, erzielt man Ergebnisse, die die Gefahr, die mit dem Virus verbunden sein soll, etwas relativieren. So finden Yang-Yang et al. (2007) keinerlei statistische Belege dafür, dass ein Ausbruch in der Türkei durch Übertragung von Mensch-zu-Mensch verursacht wurde und die statistischen Belege, die sie für einen Ausbruch in Sumatra gefunden zu haben glauben, sind Junk, denn sie verletzten die Parität mit einem Wertebereich von 0,61 bis 2,14:

Es gibt keinerlei Anhaltspunkt dafür, dass von H5N1 derzeit und in absehbarer Zeit eine Gefahr für Menschen ausgeht oder ausgehen wird. Alles, was dazu in den Medien berichtet und von interessierten Kreisen verbreitet wird, dient der Panikmache, der Vorbereitung einer menschengemachten Pandemie, die als zoonotische H5N1-Pandemie ausgegeben werden wird oder dem Zweck, die Legitimation dafür zu schaffen, Milliarden Steuergelder in den Koffern von Pharmafia-Unternehmen zu vergraben.

---

Mehr zum Thema:

• H5N1-Vogelgrippe: Ist die nächste Inszenierung einer Pandemie bereits in der Warteschleife?
• Nach der Pandemie ist vor der Pandemie: Die WHO bringt H5N1 in Stellung
• Deja-Flu: Dr. Tedros und die Vogelgrippe – Die Vorbereitungen auf die nächste (Fake-)Pandemie laufen auf Hochtouren

---

Featured Image (Quelle)

Falls Sie unsere Arbeit unterstützen, und dafür sorgen wollen, dass bei ScienceFiles auch weiterhin das Rad rund läuft, dann kaufen Sie uns doch einen Kaffee:

---

---

Oder unterstützen Sie uns auf einem der folgenden Wege Unser herzlicher Dank ist Ihnen sicher! DENN: ScienceFiles lebt von Spenden. Helfen Sie uns, ScienceFiles auf eine solide finanzielle Basis zu stellen, damit Sie uns auch morgen noch lesen können!

---

Wir haben drei sichere Spendenmöglichkeiten:

Donorbox

Unterstützen Sie ScienceFiles

---

Unsere eigene ScienceFiles-Spendenfunktion

---

Unser Spendenkonto bei Halifax:

ScienceFiles Spendenkonto: HALIFAX (Bitte angeben: Zahlungsempfänger: Michael Klein, Zahlungszweck: ScienceFiles-Spende / Schenkung):

• IBAN: GB15 HLFX 1100 3311 0902 67
• BIC: HLFXGB21B24

---

Folgen Sie uns auf Telegram.

---

Anregungen, Hinweise, Kontakt? -> Redaktion @ Sciencefiles.org

---